Last reviewed · How we verify
S-Amlodipine, Telmisartan
At a glance
| Generic name | S-Amlodipine, Telmisartan |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)
- A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome (PHASE4)
- Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers (PHASE1)
- The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy (PHASE4)
- Non-invasive Haemodynamic Assessment in Hypertension (NA)
- Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled (PHASE4)
- S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension (PHASE4)
- CKD-828 (80/5mg) Pharmacokinetic Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-Amlodipine, Telmisartan CI brief — competitive landscape report
- S-Amlodipine, Telmisartan updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI